Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
2000 1
2004 1
2009 4
2010 2
2011 2
2012 6
2013 4
2014 8
2015 10
2016 16
2017 21
2018 20
2019 26
2020 21
2021 35
2022 11
Text availability
Article attribute
Article type
Publication date

Search Results

171 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Implementing genomic medicine in the clinic: the future is here.
Manolio TA, Chisholm RL, Ozenberger B, Roden DM, Williams MS, Wilson R, Bick D, Bottinger EP, Brilliant MH, Eng C, Frazer KA, Korf B, Ledbetter DH, Lupski JR, Marsh C, Mrazek D, Murray MF, O'Donnell PH, Rader DJ, Relling MV, Shuldiner AR, Valle D, Weinshilboum R, Green ED, Ginsburg GS. Manolio TA, et al. Genet Med. 2013 Apr;15(4):258-67. doi: 10.1038/gim.2012.157. Epub 2013 Jan 10. Genet Med. 2013. PMID: 23306799 Free PMC article. Review.
Although the potential for genomics to contribute to clinical care has long been anticipated, the pace of defining the risks and benefits of incorporating genomic findings into medical practice has been relatively slow. ...Key infrastructure needs included an …
Although the potential for genomics to contribute to clinical care has long been anticipated, the pace of defining the risks a …
Medulloblastoma in the age of molecular subgroups: a review.
Juraschka K, Taylor MD. Juraschka K, et al. J Neurosurg Pediatr. 2019 Oct 1;24(4):353-363. doi: 10.3171/2019.5.PEDS18381. J Neurosurg Pediatr. 2019. PMID: 31574483 Review.
With these recent discoveries in mind, the current state of medulloblastoma treatment and clinical trials is reviewed, including a novel risk stratification system that accounts for the molecular biomarkers of patients with a high risk for refractory disease. Lastly, criti …
With these recent discoveries in mind, the current state of medulloblastoma treatment and clinical trials is reviewed, including a no …
How to use liquid biopsies to treat patients with cancer.
De Mattos-Arruda L, Siravegna G. De Mattos-Arruda L, et al. ESMO Open. 2021 Apr;6(2):100060. doi: 10.1016/j.esmoop.2021.100060. Epub 2021 Feb 26. ESMO Open. 2021. PMID: 33647598 Free PMC article. Review.
Cell-free tumor DNA (ctDNA), a form of liquid biopsy, is a noninvasive biomarker that can be isolated from patients' blood and other biofluids. An increasing body of evidence has demonstrated clinical utility of plasma ctDNA profiling to select patients for genomic- …
Cell-free tumor DNA (ctDNA), a form of liquid biopsy, is a noninvasive biomarker that can be isolated from patients' blood and other bioflui …
Bone regeneration strategies: Engineered scaffolds, bioactive molecules and stem cells current stage and future perspectives.
Ho-Shui-Ling A, Bolander J, Rustom LE, Johnson AW, Luyten FP, Picart C. Ho-Shui-Ling A, et al. Biomaterials. 2018 Oct;180:143-162. doi: 10.1016/j.biomaterials.2018.07.017. Epub 2018 Jul 11. Biomaterials. 2018. PMID: 30036727 Free PMC article. Review.
The majority of currently available reviews focus on strategies that are still at the early stages of development and use mostly in vitro experiments with cell lines or stem cells. Here, we focus on what is already implemented in the clinics, what is currently in …
The majority of currently available reviews focus on strategies that are still at the early stages of development and use mostly in vitro ex …
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.
Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, Herman GE, Hufnagel SB, Klein TE, Korf BR, McKelvey KD, Ormond KE, Richards CS, Vlangos CN, Watson M, Martin CL, Miller DT. Kalia SS, et al. Genet Med. 2017 Feb;19(2):249-255. doi: 10.1038/gim.2016.190. Epub 2016 Nov 17. Genet Med. 2017. PMID: 27854360 Free article.
It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures.To promote standardized reporting of actionable information from clinical genomic sequencing, in 2013, the American Colleg …
It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedu …
Implementing precision cancer medicine in the genomic era.
Chen HZ, Bonneville R, Roychowdhury S. Chen HZ, et al. Semin Cancer Biol. 2019 Apr;55:16-27. doi: 10.1016/j.semcancer.2018.05.009. Epub 2018 May 30. Semin Cancer Biol. 2019. PMID: 29857039 Review.
In this review, we will discuss different facets of utilizing genomic data to direct the increasingly complex care of cancer patients. We discuss the enlarging compendium of actionable genomic alterations and the development of novel molecular diagnostic assa …
In this review, we will discuss different facets of utilizing genomic data to direct the increasingly complex care of cancer p …
Performance and Application of 16S rRNA Gene Cycle Sequencing for Routine Identification of Bacteria in the Clinical Microbiology Laboratory.
Church DL, Cerutti L, Gürtler A, Griener T, Zelazny A, Emler S. Church DL, et al. Clin Microbiol Rev. 2020 Sep 9;33(4):e00053-19. doi: 10.1128/CMR.00053-19. Print 2020 Sep 16. Clin Microbiol Rev. 2020. PMID: 32907806 Free PMC article. Review.
Finally, the potential for whole-genome analysis by next-generation sequencing (NGS) to replace 16S sequencing for routine diagnostic use is presented for several applications, including the barriers that must be overcome to fully implement newer genomic methods in …
Finally, the potential for whole-genome analysis by next-generation sequencing (NGS) to replace 16S sequencing for routine diagnostic use is …
Transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to animals: an updated review.
Salajegheh Tazerji S, Magalhães Duarte P, Rahimi P, Shahabinejad F, Dhakal S, Singh Malik Y, Shehata AA, Lama J, Klein J, Safdar M, Rahman MT, Filipiak KJ, Rodríguez-Morales AJ, Sobur MA, Kabir F, Vazir B, Mboera L, Caporale M, Islam MS, Amuasi JH, Gharieb R, Roncada P, Musaad S, Tilocca B, Koohi MK, Taghipour A, Sait A, Subbaram K, Jahandideh A, Mortazavi P, Abedini MA, Hokey DA, Hogan U, Shaheen MNF, Elaswad A, Elhaig MM, Fawzy M. Salajegheh Tazerji S, et al. J Transl Med. 2020 Sep 21;18(1):358. doi: 10.1186/s12967-020-02534-2. J Transl Med. 2020. PMID: 32957995 Free PMC article. Review.
Therefore, this study aimed to gather information about the reported cases of COVID-19 transmission in animals through a literary review of works published in scientific journals and perform genomic and phylogenetic analyses of SARS-CoV-2 isolated from animal hosts. Althou …
Therefore, this study aimed to gather information about the reported cases of COVID-19 transmission in animals through a literary review of …
Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis.
Taber A, Christensen E, Lamy P, Nordentoft I, Prip F, Lindskrog SV, Birkenkamp-Demtröder K, Okholm TLH, Knudsen M, Pedersen JS, Steiniche T, Agerbæk M, Jensen JB, Dyrskjøt L. Taber A, et al. Nat Commun. 2020 Sep 25;11(1):4858. doi: 10.1038/s41467-020-18640-0. Nat Commun. 2020. PMID: 32978382 Free PMC article.
Overtreatment with cisplatin-based chemotherapy is a major issue in the management of muscle-invasive bladder cancer (MIBC), and currently none of the reported biomarkers for predicting response have been implemented in the clinic. Here we perform a comprehensive mu …
Overtreatment with cisplatin-based chemotherapy is a major issue in the management of muscle-invasive bladder cancer (MIBC), and currently n …
Developing next generation immunomodulatory drugs and their combinations in multiple myeloma.
Thakurta A, Pierceall WE, Amatangelo MD, Flynt E, Agarwal A. Thakurta A, et al. Oncotarget. 2021 Jul 20;12(15):1555-1563. doi: 10.18632/oncotarget.27973. eCollection 2021 Jul 20. Oncotarget. 2021. PMID: 34316334 Free PMC article.
Understanding drug mechanisms and their application in combination settings as well as the unique disease biology considerations from newly diagnosed (NDMM), relapsed/refractory (RRMM), and maintenance settings will be vital to guide the development of future MM therapies …
Understanding drug mechanisms and their application in combination settings as well as the unique disease biology considerations from newly …
171 results